Pharmacy

Top Medical News
Eosinophils confer protective benefit in acetaminophen-induced acute liver injury
an hour ago
Hepatic recruitment of eosinophils appears to play a protective role during acute liver injury caused by acetaminophen overdose, reveals a recent study.
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
Stephen Padilla, 2 hours ago
Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.
Another breakthrough for HIV: Fourth patient goes into long-term remission
Audrey Abella, 4 hours ago
Hope springs yet again in the field of HIV treatment, as another HIV patient (reportedly the fourth in the world) goes into remission 3 decades following diagnosis. The patient stopped antiretroviral therapy (ART) after receiving allogeneic hematopoietic stem cell transplantation (HCT) of CCR5-Δ32/Δ32 donor cells for acute myelogenous leukaemia (AML).
Relugolix-CT benefit for endometriosis-associated pain sustained through week 104
Elaine Soliven, 14 hours ago
Long-term combination therapy with relugolix plus oestradiol and norethindrone (relugolix-CT) shows sustained reductions in dysmenorrhoea and non-menstrual pelvic pain (NMPP) for up to 2 years in premenopausal women with endometriosis, according to the SPIRIT extension* study presented at ESHRE 2022.
Canagliflozin improves HF symptoms, QoL regardless of diabetes status
Yesterday
Treatment with the sodium‐glucose cotransporter 2 inhibitor canagliflozin protects against cardiovascular events in patients with comorbid type 2 diabetes (T2D) and chronic kidney disease (CKD), with a larger absolute benefit for total cardiovascular than first cardiovascular events, according to a post hoc analysis.
Teclistamab demonstrates clinical activity for R/R MM
Audrey Abella, Yesterday
The T-cell-redirecting bispecific antibody teclistamab induced deep and durable responses in patients with triple-class-exposed relapsed or refractory multiple myeloma (R/R MM), findings from the phase I/II MajesTEC-1 trial have shown.
1 week off methotrexate works okay for RA patients receiving flu shot
Yesterday
Temporarily discontinuing methotrexate treatment for 1 week appears to induce satisfactory response to a seasonal influenza vaccine in patients with rheumatoid arthritis (RA), with a similar effect as a 2-week interruption schedule, according to a study.
Special Reports
Product Highlight - Canespro
15 Jun 2022
Bifonazole Anti-Fungal Cream 1% w/w
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Product Highlight - Pontevia
16 Mar 2022
Galcanezumab Injection
Product Highlight - Bilaxten ODT
16 Mar 2022
Bilastine 10 mg orodispersible tablet
Product Highlight - Locoa
01 Dec 2021
Esflurbiprofen 40 mg transdermal patch
Product Highlight - Rinvoq
01 Dec 2021
Upadacitinib 15 mg XR-FC tab
Product Highlight - Evenity
01 Dec 2021
Romosozumab 105 mg/1.17 mL soln for inj
Conference Reports
Methenamine hippurate as good as antibiotic prophylaxis for recurrent UTI
Elvira Manzano, 10 Aug 2022
Daily antibiotics are the current guideline-recommended standard for urinary tract infection (UTI). Interestingly, in the randomized, open-label ALTAR trial presented at EAU 2022, the urinary antiseptic methenamine hippurate was noninferior to antibiotic prophylaxis in women with recurrent UTI.
Long-acting injectable HIV drug works for all ages
Jairia Dela Cruz, 07 Aug 2022
The long-acting combination of cabotegravir plus rilpivirine, administered as monthly or once-every-2-months jabs, appears to be effective in both older and younger patients living with HIV, with most maintaining virologic suppression through week 96, according to pooled data from the phase III ATLAS, FLAIR, and ATLAS-2M studies.
Expectant mums’ use of dolutegravir safe for babies
Jairia Dela Cruz, 04 Aug 2022

Treatment with dolutegravir during pregnancy does not appear to pose an excess risk of adverse birth outcomes, according to two studies presented at the 24th International AIDS Conference in Montreal, Canada.

Abiraterone-olaparib confers clinical benefit for mCRPC patients
Audrey Abella, 04 Aug 2022
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Ibalizumab induces consistent HIV response when paired with partially active agents
Tristan Manalac, 03 Aug 2022
Ibalizumab appears to be a promising treatment option in heavily treatment-experienced (HTE) patients with multidrug-resistant HIV-1 infections, yielding consistent efficacy outcomes even when used in combination with partially active agents, according to a study presented at the 24th International AIDS Conference (AIDS 2022).
Heparin dose may not affect antepartum VTE incidence
Roshini Claire Anthony, 02 Aug 2022

In pregnant women with a history of venous thromboembolism (VTE), receipt of low-molecular-weight heparin (LMWH) at either a weight-adjusted intermediate-dose or fixed low-dose during the antepartum and postpartum periods results in similar VTE incidence, according to findings of the Highlow study. However, there was a numerically lower incidence of VTE during the postpartum period with intermediate-dose LMWH.

Fezolinetant reduces hot flashes during menopause
Roshini Claire Anthony, 01 Aug 2022

The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.

Product Highlights
CME Modules